CY1121368T1 - Αντισωματα anti-asic1 και χρησεις αυτων - Google Patents
Αντισωματα anti-asic1 και χρησεις αυτωνInfo
- Publication number
- CY1121368T1 CY1121368T1 CY20191100246T CY191100246T CY1121368T1 CY 1121368 T1 CY1121368 T1 CY 1121368T1 CY 20191100246 T CY20191100246 T CY 20191100246T CY 191100246 T CY191100246 T CY 191100246T CY 1121368 T1 CY1121368 T1 CY 1121368T1
- Authority
- CY
- Cyprus
- Prior art keywords
- asic1
- antibodies
- cells expressing
- induced
- acid
- Prior art date
Links
- 101710099904 Acid-sensing ion channel 1 Proteins 0.000 abstract 3
- 102100021624 Acid-sensing ion channel 1 Human genes 0.000 abstract 3
- 101000754290 Homo sapiens Acid-sensing ion channel 1 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000048484 human ASIC1 Human genes 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592837P | 2012-01-31 | 2012-01-31 | |
| US201261644038P | 2012-05-08 | 2012-05-08 | |
| US201261692925P | 2012-08-24 | 2012-08-24 | |
| PCT/US2013/023784 WO2013116296A1 (en) | 2012-01-31 | 2013-01-30 | Anti-asic1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121368T1 true CY1121368T1 (el) | 2020-05-29 |
Family
ID=47666522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100246T CY1121368T1 (el) | 2012-01-31 | 2019-02-27 | Αντισωματα anti-asic1 και χρησεις αυτων |
| CY20211100968T CY1124778T1 (el) | 2012-01-31 | 2021-11-09 | Αντισωματα anti-asic1 και χρησεις αυτων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100968T CY1124778T1 (el) | 2012-01-31 | 2021-11-09 | Αντισωματα anti-asic1 και χρησεις αυτων |
Country Status (33)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3453723T3 (da) | 2012-01-31 | 2021-09-13 | Regeneron Pharma | Anti-ASIC1-antistoffer og anvendelser deraf |
| WO2015160858A2 (en) * | 2014-04-15 | 2015-10-22 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind wisp1 |
| KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| CN105233286B (zh) * | 2015-09-10 | 2018-10-30 | 上海交通大学医学院 | 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途 |
| CN105713089B (zh) * | 2016-02-26 | 2019-08-06 | 上海科技大学 | 一种特异性抑制酸敏感离子通道i型的全人抗体 |
| WO2018085441A1 (en) * | 2016-11-01 | 2018-05-11 | Berg Llc | Filamin b binding proteins and uses thereof |
| CN111936517B (zh) * | 2018-01-26 | 2025-04-18 | 瑞泽恩制药公司 | 抗tmprss2抗体和抗原结合片段 |
| GB2598698B (en) * | 2019-06-04 | 2024-09-18 | Univ Shanghai Technology | Affinity-maturated anti-ASICIa antibodies |
| US12441789B2 (en) * | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| US20230287107A1 (en) * | 2019-07-23 | 2023-09-14 | Shanghaitech University | Asic1 channel antagonist antibody |
| MX2022003074A (es) * | 2019-09-13 | 2022-06-14 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-cd371, y usos de los mismos. |
| MX2024001808A (es) * | 2021-08-09 | 2024-02-29 | Merck Patent Gmbh | Proteinas que desacoplan la citotoxicidad tumoral mediada por celulas t de la liberacion de citoquinas proinflamatorias. |
| AU2022337142A1 (en) * | 2021-09-02 | 2024-03-07 | Memorial Hospital For Cancer And Allied Diseases | Anti-dll3 antibodies and uses thereof |
| CN119331085B (zh) * | 2024-10-16 | 2025-03-14 | 中国科学院合肥物质科学研究院 | 沙贝冠状病毒广谱中和抗体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2759373B1 (fr) | 1997-02-11 | 2001-05-04 | Centre Nat Rech Scient | Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications |
| DE69836591T2 (de) | 1997-10-29 | 2007-09-20 | Mcgill University, Montreal | Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen |
| US6287859B1 (en) | 1998-08-05 | 2001-09-11 | Centre National De La Recherche | Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel |
| CA2304494A1 (en) | 2000-04-20 | 2001-10-20 | Philippe Seguela | A novel heteromultimeric ion channel receptor and uses thereof |
| US6635432B1 (en) | 2000-04-25 | 2003-10-21 | University Of Iowa Research Foundation | Peptide potentiation of acid-sensory ion channel in pain |
| US7132505B1 (en) | 2001-05-10 | 2006-11-07 | Centre National De La Recherche Scientifique - Cnrs | Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker |
| CA2352702A1 (en) * | 2001-07-18 | 2003-01-18 | Philippe Seguela | Novel human proton gated ion channel |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2479927C (en) * | 2002-03-29 | 2013-03-12 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| US20030186860A1 (en) | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
| US20070197583A1 (en) | 2002-03-29 | 2007-08-23 | Welsh Michael J | Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction |
| WO2005025518A2 (en) * | 2003-09-11 | 2005-03-24 | The Uab Research Foundation | Inhibition of inward sodium currents in cancer |
| WO2005074923A1 (en) | 2004-02-03 | 2005-08-18 | Agt Biosciences Limited | Methods and compositions |
| JP2007530664A (ja) | 2004-03-30 | 2007-11-01 | ペインセプター ファーマ コーポレーション | ゲートイオンチャンネルを調節するための組成物及び方法 |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US7192500B2 (en) | 2004-04-30 | 2007-03-20 | Kimberly-Clark Worldwide, Inc. | Process for making a garment including an absorbent assembly |
| US8030442B2 (en) | 2004-09-16 | 2011-10-04 | Morehouse School Of Medicine | Treatment of injury to the brain by inhibition of acid sensing ion channels |
| CN105085678B (zh) * | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| CA2604357C (en) * | 2005-04-26 | 2012-01-17 | Pfizer Inc. | P-cadherin antibodies |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| WO2008007648A1 (fr) * | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| EP2043650A2 (en) | 2006-07-14 | 2009-04-08 | Medical Research Council | Treatment for demyelinating disease |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US7598039B2 (en) | 2007-01-30 | 2009-10-06 | Academia Sinica | Treatment of insulin resistance |
| WO2008119360A1 (en) | 2007-04-03 | 2008-10-09 | ILEGUSAVNID, Genetics Resource Centre Minestry of Social Affairs and Health | Amiloride sensitive sodium channels associated with panic disorders |
| WO2008134659A2 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| EP2853897A1 (en) * | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
| US20090291150A1 (en) | 2008-05-21 | 2009-11-26 | University Of Iowa Research Foundation | Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity |
| FR2932091B1 (fr) | 2008-06-06 | 2012-12-28 | Centre Nat Rech Scient | Effets analgesiques de la toxine peptidique apetx2 |
| JP2012508017A (ja) * | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗ｄｌｌ４抗体及びその使用 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| GB0922434D0 (en) * | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| CN102234316B (zh) * | 2010-05-07 | 2014-01-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有增强酸感受离子通道1a电流作用的多肽及其用途 |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| DK3453723T3 (da) | 2012-01-31 | 2021-09-13 | Regeneron Pharma | Anti-ASIC1-antistoffer og anvendelser deraf |
-
2013
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active Active
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en not_active Ceased
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/en active
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 SM SM20210628T patent/SMT202100628T1/it unknown
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
-
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613A1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
-
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
-
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
-
2019
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
-
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121368T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
| CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
| CY1124412T1 (el) | Aνti-dkk-1 αντισωματα | |
| CY1121097T1 (el) | Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| CY1126072T1 (el) | Περιοχες gla ως θεραπευτικοι παραγοντες | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
| CY1121736T1 (el) | Άλατα aramchol | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| CY1120337T1 (el) | Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης | |
| CY1118714T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
| EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| CY1118588T1 (el) | Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| CY1116940T1 (el) | Φλυκταινες εμπλουτισμενες σε φωσφολιπιδιο που φερουν παραγοντα ιστου εχουσες αιμοστατικες δραστικοτητες και χρησεις αυτων | |
| EA201890941A1 (ru) | Программируемые универсальные клеточные рецепторы и способы их применения | |
| MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 |